Jiang JK, et al. (2010) Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators with the tumor cell particular M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 20(11):3387?393. 17. Vander Heiden MG, et al. (2010) Identification of little molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79(eight):1118?124. 18. Flory W, Peczon BD, Koeppe RE, Spivey HO (1974) Kinetic properties of rat liver pyruvate kinase at cellular concentrations of enzyme, substrates and modifiers. Biochem J 141(1):127?31. 19. Burton RL, Chen S, Xu XL, Grant GA (2009) Transient kinetic analysis of the interaction of L-serine with Escherichia coli D-3-phosphoglycerate dehydrogenase reveals the mechanism of V-type regulation as well as the order of effector binding. Biochemistry 48(51):12242?2251. 20. Kato H, Fukuda T, Parkison C, McPhie P, Cheng SY (1989) Cytosolic thyroid hormonebinding protein is really a monomer of pyruvate kinase. Proc Natl Acad Sci USA 86(20): 7861?865.21. Ashizawa K, Willingham MC, Liang CM, Cheng SY (1991) In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated through fructose 1,6-bisphosphate. J Biol Chem 266(25):16842?6846. 22. Ashizawa K, McPhie P, Lin KH, Cheng SY (1991) An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6bisphosphate. Biochemistry 30(29):7105?111. 23. Larsen TM, Benning MM, Rayment I, Reed GH (1998) Structure of your bis(Mg2+)-ATPoxalate complex in the rabbit muscle pyruvate kinase at two.2-Chloro-5-hydroxyisonicotinic acid custom synthesis 1 A resolution: ATP binding over a barrel.Formula of Spiro[3.3]heptan-2-amine hydrochloride Biochemistry 37(18):6247?255. 24. Morgan HP, et al. (2010) Allosteric mechanism of pyruvate kinase from Leishmania mexicana makes use of a rock and lock model. J Biol Chem 285(17):12892?2898. 25. Consler TG, Woodard SH, Lee JC (1989) Effects of principal sequence variations on the worldwide structure and function of an enzyme: A study of pyruvate kinase isozymes. Biochemistry 28(22):8756?764. 26. Williams R, Holyoak T, McDonald G, Gui C, Fenton AW (2006) Differentiating a ligand’s chemical requirements for allosteric interactions from those for protein binding. Phenylalanine inhibition of pyruvate kinase. Biochemistry 45(17):5421?429. 27. Kumar Y, et al. (2010) In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines. Tumour Biol 31(2):69?7. 28. Mazurek S, Eigenbrodt E (2003) The tumor metabolome. Anticancer Res 23(2A): 1149?154. 29. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R (1992) Double part for pyruvate kinase type M2 in the expansion of phosphometabolite pools located in tumor cells. Crit Rev Oncog 3(1-2):91?15.PMID:24065671 30. Zhou CF, et al. (2012) Pyruvate kinase form M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life 64(9):775?82. 31. Hardin CD, Roberts TM (1994) Metabolism of exogenously applied fructose 1,6bisphosphate in hypoxic vascular smooth muscle. Am J Physiol 267(6 Pt 2):H2325 2332. 32. Chaneton B, et al. (2012) Serine is usually a organic ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424):458?62. 33. Walsh MJ, et al. (2011) 2-Oxo-N-aryl-1,2,three,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell precise M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 21(21):6322?327. 34. Anastasiou D, et al. (2012) Pyruvate kinase M2 activators market tetramer formation and suppress tumorigenesis. Nat Chem Biol eight(10):839?47. 35. Cheng SY, Leonard JL, Davi.